Photo Credit: Elsa Olofsson
Scientific Frontline: Extended "At a Glance" Summary: Pharmacotherapy for Compulsive Sexual Behavior Disorder
The Core Concept: Compulsive sexual behavior disorder is a psychological condition characterized by persistent, recurring difficulties in controlling sexual impulses and behaviors. Recent clinical trials demonstrate that the medications fluoxetine and naltrexone yield comparable reductions in these symptoms over an eight-week period.
Key Distinction/Mechanism: While both pharmacological treatments are effective, their symptom reduction trajectories differ significantly. Naltrexone, a medication utilized for substance use disorders, produces an early reduction in symptoms, whereas improvements from the antidepressant fluoxetine emerge later in the treatment cycle.
Major Frameworks/Components:
- Selective Serotonin Reuptake Inhibitors (SSRIs): The application of fluoxetine to modulate serotonin levels and gradually mitigate compulsive impulses.
- Opioid Antagonists: The use of naltrexone to target behavioral addiction pathways, yielding more rapid symptom relief.
- Temporal Trajectory Variations: The clinical observation that different pharmacological agents alter the speed and pattern of symptom remission, despite achieving similar endpoints.
Branch of Science: Psychiatry, Psychopharmacology, Behavioral Science.
Future Application: Clinicians will be able to leverage these findings to personalize treatment plans based on a patient's individual circumstances, tolerance for specific adverse effects (such as naltrexone-induced nausea), and desired clinical response time. Subsequent research will investigate long-term outcomes and evaluate efficacy across broader demographics, particularly in female populations.
Why It Matters: An estimated 2 to 3 percent of the population experiences compulsive sexual behavior disorder, yet evidence-based pharmacological interventions remain severely limited. Identifying effective comparative treatments provides critical therapeutic options to mitigate the significant distress and functional impairment caused by the condition.
Naltrexone and fluoxetine demonstrated similar results in the treatment of people with compulsive sexual behavior disorder in a new study from Karolinska Institutet. Published in BMJ Mental Health, the study found no clear differences between the medications after eight weeks of treatment, although symptom patterns changed differently over time.
Compulsive sexual behavior disorder is characterized by recurring difficulties in controlling sexual impulses and behaviors, which can lead to distress and negative consequences in everyday life. Although the condition is estimated to affect 2 to 3 percent of the population, knowledge about pharmacological treatment remains limited.
In the new study, researchers compared the antidepressant selective serotonin reuptake inhibitor (SSRI) fluoxetine with naltrexone, a medication used, among other things, to treat substance use disorders. Both medications are sometimes prescribed for compulsive sexual behavior disorder, but evidence regarding their effects has so far been limited.
A total of 80 individuals who met the diagnostic criteria for the disorder participated in the study. Participants were randomly assigned to receive either fluoxetine or naltrexone for eight weeks, followed by a six-week treatment-free period. The study was conducted at ANOVA, Karolinska University Hospital in Stockholm.
Different symptom trajectories over time The researchers found that symptoms decreased in both treatment groups during the intervention period, but there was no statistically significant difference between the medications after eight weeks of treatment. However, differences were observed in how symptoms developed over time. Individuals treated with naltrexone experienced an early reduction in symptoms, whereas improvements in the fluoxetine group emerged later during the treatment period.
“Knowledge about pharmacological treatment for compulsive sexual behavior disorder is still limited. Our findings suggest that treatment choices may need to be based on the patient’s individual circumstances, preferences, and which adverse effects are considered acceptable,” says Josephine Savard, consultant psychiatrist at ANOVA and researcher at Karolinska Institutet and Umeå University.
The researchers also examined how well participants tolerated the treatments. Most reported some form of side effect, although these were generally mild to moderate in severity. The most common adverse effects differed between the medications. Reduced sexual desire was reported in both groups, while nausea was more common among those receiving naltrexone. Two participants treated with fluoxetine discontinued treatment due to pronounced or severe adverse effects.
The researchers emphasize that further studies are needed to investigate long-term effects and to identify which patients may benefit most from each treatment. They also note that the study population consisted almost entirely of men, meaning that the findings cannot automatically be generalized to women.
Funding: Funding was provided by, among others, the Swedish Research Council, Umeå University, ALF funding from Region Stockholm and Region Västerbotten, as well as several Swedish research foundations. The researchers report no conflicts of interest.
Published in journal: BMJ Mental Health
Title: Randomised controlled trial of fluoxetine versus naltrexone in compulsive sexual behaviour disorder
Authors: Josephine Savard, Marta Piwowar, Roberth Adebahr, Markus Byström, Jonas Hallberg, Cecilia Dhejne, Katarina Görts Öberg, and Jussi Jokinen
Source/Credit: Karolinska Institutet
Edited by: Scientific Frontline
Reference Number: psyc100726_01